The Imcyse technology platform has the potential to address a wide range of indications in the vast field of immunology. ImotopesTM represent a next generation, potentially curative approach to severe chronic autoimmune diseases.
Our initial target indications focus on severe, chronic autoimmune diseases such as type 1 diabetes and multiple sclerosis which we have advanced into the clinic. In addition, we have a number of pre-clinical programs in development, including Neuromyelitis Optica, Rheumatoid Arthritis, Celiac disease and others. In these indications existing therapies can, at-best, manage the disease symptoms and slow down their progression, often with frequent and severe adverse effects. Currently, no therapeutic cures available.
In addition to autoimmune diseases, Imcyse’s technology has demonstrated efficacy of concept in animal models for allergies and in the prevention of skin graft rejection.
The technology could also be applied as an « add-on » therapy to other drugs or biologics to prevent the progression of immunogenicity and loss of efficacy upon chronic administration - such as monoclonal antibodies or replacement enzymes. Furthermore, it can eliminate the immune response against viral vectors that are used in gene therapies